Processa Pharmaceuticals (PCSA) announced the pricing of a public offering of 28M shares of common stock at a public offering price of 25c per share. The closing of the offering is expected to occur on or about June 18. H.C. Wainwright is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $7M. Processa intends to use the net proceeds from the offering to continue the Phase 2 clinical trial for NCG-Cap.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa Pharmaceuticals Announces Licensing Deal with Intact
- Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics
- Processa Pharmaceuticals files to sell 20.59M shares of common stock, warrants
- Processa to engage potential partners, investors at BIO International Convention
- Processa announces presentation, publication of abstracts at ASCO meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue